Regarding the current clinical practice guidelines for chronic hepatitis B management [3, 23], patients with malignant tumors who receive chemotherapy should be regularly monitored for ALT and HBV DNA levels and treated with NA therapy upon confirmation of HBV reactivation prior to ALT elevation. This evidence concerns the gene GPT and chronic hepatitis B virus infection.